Three years after Michael Davidson and his colleagues sold the omega-3 drug Epanova to AstraZeneca ($AZN) in the $443 million Omthera buyout, the biotech exec has rounded up some fresh support from a seasoned ally in the venture world to begin building a new biotech focused on cardiovascular disease.
{iframe}http://www.fiercebiotech.com/story/biotech-vet-grabs-astrazeneca-drug-26m-start-building-new-cardio-biotech/2016-02-18{/iframe}